losartan has been researched along with apigenin in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Strassburg, CP; Tukey, RH | 1 |
| Delabio, LC; Dutra, JP; Hembecker, M; Kita, DH; Moure, VR; Pereira, GDS; Scheiffer, G; Valdameri, G; Zattoni, IF | 1 |
| Chen, LG; Chen, MC; Chen, RJ; Gong, Y; Hu, GX; Huang, CK; Lin, GT; Sun, W; Wang, Z; Zeng, DL | 1 |
2 review(s) available for losartan and apigenin
| Article | Year |
|---|---|
Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
Topics: Autoimmunity; Chromosome Mapping; Glucuronides; Glucuronosyltransferase; Humans; Hyperbilirubinemia; Neoplasms; Steroids; Terminology as Topic | 2000 |
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Proteins; Neoplastic Stem Cells | 2022 |
1 other study(ies) available for losartan and apigenin
| Article | Year |
|---|---|
Inhibitory Effect of Apigenin on Losartan Metabolism and CYP2C9 Activity in vitro.
Topics: Animals; Apigenin; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2C9 Inhibitors; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Humans; Losartan; Male; Microsomes, Liver; Rats; Rats, Sprague-Dawley | 2016 |